Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: biologics

ADOBE STOCK | Feodora

The Great Pediatric Debate 2024: Cessation or Continuation of Biologics in sJIA Lung Disease?

Ruth Jessen Hickman, MD  |  November 23, 2024

Washington D.C.—At a Sunday, Nov. 17, Pediatrics Great Debate session of ACR Convergence, speakers argued whether patients with systemic juvenile idiopathic arthritis (sJIA) should continue their interleukin (IL) 1/IL-6 biologics if lung disease is suspected. Randy Q. Cron, MD, PhD, the director of the Division of Pediatric Rheumatology at the University of Alabama at Birmingham,…

Filed under:ACR ConvergenceConditionsPediatric Conditions Tagged with:ACR Convergence 2024sJIAsJIA-associated lung disease

3 AC&R Study Summaries: Treat to Target in Gout, Response to Biologics in Patients with JIA, & Rehabilitation Dose in Adults with RA

Arthritis Care & Research  |  February 14, 2023

Treat to Target in Gout Monitoring & achievement of target serum urate levels By Jing Li & Gabriela Schmajuk, MD, MS Why was this study done? The ACR’s 2020 guideline for the management of gout recommends using a treat-to-target (T2T) approach to lower serum urate (SU). Using the ACR’s RISE registry, we examined the use…

Filed under:ConditionsGout and Crystalline ArthritisPediatric ConditionsResearch RheumRheumatoid Arthritis Tagged with:GoutGout Resource Centerjuvenile idiopathic arthritis (JIA)

Ongoing Advocacy Efforts Seek Use of Complex Administration Codes for Biologics

From the College  |  August 8, 2022

Ongoing ACR advocacy efforts are working to keep biologic drugs accessible to rheumatology patients, defending the ability of rheumatology practices to use the complex chemotherapy codes for administration of biologic therapies.

Filed under:Biologics/DMARDsLegislation & Advocacy Tagged with:ACR advocacybiologic therapiesLocal Coverage Article (LCA)Medicare Administrative Contractors (MACs)

The Microbiome in Pediatric Rheumatic Diseases

When to Start Biologics for pJIA

Staff  |  January 4, 2022

Nonserious Infection Rates with Biologics Used to Treat RA

Arthritis & Rheumatology  |  September 27, 2021

Bechman et al. set out to describe the frequency and predictors of nonserious infections and compare incidence rates across biologic DMARDs. They found all bDMARDs are associated with a greater risk of nonserious infection, with differences observed between agents. Although unmeasured confounding must be considered, the magnitude of effect is large.

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis & Rheumatologybiologic disease-modifying antirheumatic drugsbiologic DMARDsInfectionResearchRheumatoid Arthritis (RA)

Biologics in Rheumatology: Revolution & Perspectives

Lara C. Pullen, PhD  |  December 8, 2020

A great deal of progress has been made in the treatment of rheumatic diseases—from glucocorticoid use to the advent of biologic therapies. Gerd Burmester, MD, discussed this progress and the impact of biologics in this year’s Phillip Hench, MD, Memorial Lecture.

Filed under:ACR ConvergenceBiologics/DMARDsMeeting Reports Tagged with:ACR Convergence 2020biologic drugsBiologicsBiosimilarsmeeting reports

The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?

Jason Liebowitz, MD, FACR  |  November 9, 2020

ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…

Filed under:ACR ConvergenceDrug UpdatesMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2020ACR Convergence 2020 – RA

Biologics May Prevent Cardiovascular Events in RA Patients

Arthritis & Rheumatology  |  August 26, 2020

RA patients experience a higher rate of cardiovascular disease (CVD) events than controls. In a new study, Karpouzas et al. determined that current biologic disease-modifying anti-rheumatic drug use is associated with reduced long-term CVD risk, protective calcification of noncalcified lesions and a lower likelihood of new plaque formation in patients with early atherosclerosis.

Filed under:Biologics/DMARDsConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis & Rheumatologybiologic DMARDsCardiovascular diseaseResearchRheumatoid Arthritis (RA)

Shidlovski / shutterstock.com

Studies Suggest Similar Risks for Biologics vs. Conventional Therapies for Rheumatoid Arthritis

Bryn Nelson, PhD  |  May 15, 2020

Two new studies delving into the relative safety of biologic drugs prescribed for rheumatoid arthritis (RA) have concluded that real-world applications of abatacept and tumor necrosis factor inhibitors (TNFi’s) are comparable to more conventional therapies in their associated risk of serious infections. Triple Therapy One study, in Arthritis Care & Research, found the risk of…

Filed under:ConditionsDrug UpdatesResearch RheumRheumatoid Arthritis Tagged with:abatacepttriple therapytumor necrosis factor inhibitor (TNFi)

Common Characteristics in RA Patients Who Don’t Respond to Biologics

Vanessa Caceres  |  May 18, 2019

At least 6% of patients who used biologic disease-modifying anti-rheumatic drugs (bDMARDs) suffered refractory disease, according to a recent study based on data from the British Society for Rheumatology Biologics Registry for Rheumatoid Arthritis.1 This observational study evaluated the extent of biologic refractory rheumatoid arthritis (RA). The study defined biologic refractory disease as occurring in…

Filed under:Biologics/DMARDsConditionsRheumatoid Arthritis Tagged with:biologic-refractory RArefractory rheumatoid arthritis

  • 1
  • 2
  • 3
  • …
  • 75
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences